D. Skarlos

486 total citations
16 papers, 363 citations indexed

About

D. Skarlos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, D. Skarlos has authored 16 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in D. Skarlos's work include Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). D. Skarlos is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). D. Skarlos collaborates with scholars based in Greece. D. Skarlos's co-authors include G. Klouvas, George Fountzilas, P. Kosmidis, N. Mylonakis, D. Theocharis, E. Papadakis, Ekaterini Boleti, Nicholas Pavlidis, Ph. Palamidas and E. Samantas and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

D. Skarlos

16 papers receiving 352 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
D. Skarlos 282 181 131 100 31 16 363
M.C. Berchier 363 1.3× 161 0.9× 132 1.0× 281 2.8× 20 0.6× 26 479
Dominique Herman 279 1.0× 101 0.6× 69 0.5× 228 2.3× 40 1.3× 20 444
Isabel R. Preeshagul 191 0.7× 76 0.4× 72 0.5× 106 1.1× 18 0.6× 28 306
Aravind S. Ravi Kumar 133 0.5× 86 0.5× 21 0.2× 172 1.7× 55 1.8× 34 377
S Patriarca 154 0.5× 66 0.4× 26 0.2× 68 0.7× 38 1.2× 22 290
Yi‐Zarn Wang 364 1.3× 387 2.1× 61 0.5× 65 0.7× 66 2.1× 47 567
Maciej Bączyk 163 0.6× 144 0.8× 31 0.2× 69 0.7× 124 4.0× 36 425
Jaume Trapé 85 0.3× 37 0.2× 52 0.4× 82 0.8× 39 1.3× 29 270
U. Stölzel 316 1.1× 347 1.9× 59 0.5× 71 0.7× 105 3.4× 33 491
Giovanni Boz 218 0.8× 43 0.2× 29 0.2× 89 0.9× 134 4.3× 19 303

Countries citing papers authored by D. Skarlos

Since Specialization
Citations

This map shows the geographic impact of D. Skarlos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Skarlos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Skarlos more than expected).

Fields of papers citing papers by D. Skarlos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Skarlos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Skarlos. The network helps show where D. Skarlos may publish in the future.

Co-authorship network of co-authors of D. Skarlos

This figure shows the co-authorship network connecting the top 25 collaborators of D. Skarlos. A scholar is included among the top collaborators of D. Skarlos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Skarlos. D. Skarlos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Pectasides, D., Urania Dafni, Gerasimos Aravantinos, et al.. (2008). A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.. PubMed. 27(6C). 4411–7. 5 indexed citations
2.
Christodoulou, C., et al.. (2007). Performance status (PS): a simple predictor of short-term outcome of cancer patients with solid tumors admitted to the intensive care unit (ICU).. PubMed. 27(4C). 2945–8. 30 indexed citations
3.
Timotheadou, Eleni, Helena Linardou, Jana Skřičková, et al.. (2005). VEGF165, Bcl-2, p53, COX-2 and HER-family expression in patients with stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) and correlation with clinical outcome. Journal of Clinical Oncology. 23(16_suppl). 7246–7246. 2 indexed citations
4.
Christodoulou, C., D. Anastasopoulos, S. Mellou, et al.. (2004). Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy. Anti-Cancer Drugs. 15(10). 997–999. 27 indexed citations
5.
Bafaloukos, D., Dimosthenis Tsoutsos, Haralabos P. Kalofonos, et al.. (2004). Temozolomide and cisplatin (TP) vs temozolomide (T) in patients with advanced melanoma. A randomized phase II of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology. 22(14_suppl). 7545–7545. 1 indexed citations
6.
Bafaloukos, Dimitrios, Dimosthenis Tsoutsos, Haralabos P. Kalofonos, et al.. (2004). Temozolomide and cisplatin (TP) vs temozolomide (T) in patients with advanced melanoma. A randomized phase II of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology. 22(14_suppl). 7545–7545. 1 indexed citations
7.
Christodoulou, C., et al.. (2003). Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.. PubMed. 23(1B). 737–44. 18 indexed citations
8.
Kalofonos, Haralabos P., D. Skarlos, D. Bafaloukos, et al.. (2003). A Phase II Study with CPT-11 Plus Leucovorin and Bolus IV 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma. Cancer Investigation. 21(6). 855–862. 7 indexed citations
9.
Pavlidis, Nikolaos, E. Samantas, George Fountzilas, et al.. (2003). Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.. PubMed. 22(6B). 3749–57. 17 indexed citations
10.
Aravantinos, Gerasimos, P. Kosmidis, Meletios Α. Dimopoulos, et al.. (2003). 37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results. European Journal of Cancer Supplements. 1(5). S15–S15. 2 indexed citations
11.
Fountzilas, George, E. Samantas, D. Skarlos, et al.. (1997). Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.. PubMed. 24(1 Suppl 2). S2–65. 12 indexed citations
12.
Skarlos, D., Gerasimos Aravantinos, P. Kosmidis, et al.. (1997). Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.. PubMed. 24(5 Suppl 15). S15–57. 9 indexed citations
13.
Skarlos, D., Epaminontas Samantas, N. Pavlidis, et al.. (1997). 154 Weekly chemotherapy with alternating non-cross resistant chemotherapy regimens in good-prognosis small cell lung cancer (SCLC). (Final results). Lung Cancer. 18. 42–42. 3 indexed citations
14.
Bafaloukos, Dimitrios, N. Pavlidis, D. Skarlos, et al.. (1996). Recombinant Interferon ALFA-2A in Combination With Carboplatin, Vinblastine, and Bleomycin in the Treatment of Advanced Malignant Melanoma. American Journal of Clinical Oncology. 19(3). 296–300. 9 indexed citations
15.
Skarlos, D., E. Samantas, P. Kosmidis, et al.. (1994). Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Annals of Oncology. 5(7). 601–607. 195 indexed citations
16.
Kosmidis, P., N. Mylonakis, D. Skarlos, et al.. (1994). A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. Annals of Oncology. 5(2). 159–162. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.C. Berchier Breakdown of academic impact, for papers by Dominique Herman Breakdown of academic impact, for papers by Isabel R. Preeshagul Breakdown of academic impact, for papers by Aravind S. Ravi Kumar Breakdown of academic impact, for papers by S Patriarca Breakdown of academic impact, for papers by Yi‐Zarn Wang Breakdown of academic impact, for papers by Maciej Bączyk Breakdown of academic impact, for papers by Jaume Trapé Breakdown of academic impact, for papers by U. Stölzel Breakdown of academic impact, for papers by Giovanni Boz
Rankless by CCL
2026